Disclosed are pharmaceutical compositions and methods for preventing or
treating a number of amyloid diseases, including Alzheimer's disease, prion diseases,
familial amyloid neuropathies and the like. The pharmaceutical compositions include
immunologically reactive amounts of amyloid fibril components, particularly fibril-forming
peptides or proteins. Also disclosed are therapeutic compositions and methods which
use immune reagents that react with such fibril components.
